The antidepressant Prozac is currently facing supply issues, which are causing export restrictions and making it harder for pharmacies in France to obtain the medication. The French Agency for Medicines (ANSM) has reported temporary problems in the production chain and expects the situation to improve by mid-October. In response, the agency has asked pharmaceutical companies to boost their supply by using all available stock, including safety reserves. Since early September, France has been limiting the quantity of Prozac available and banning its export to ensure patients already on the medication can continue their treatment without interruption. The ANSM has also advised that new prescriptions for Prozac should primarily be reserved for children aged 8 and older who are experiencing depressive episodes. Fluoxetine, the active ingredient in Prozac, is used to treat major depression, obsessive-compulsive disorder, and bulimia. It is the only antidepressant approved for treating certain depressive episodes in children from the age of 8. Other widely prescribed psychiatric medications, such as quetiapine for schizophrenia and lithium for bipolar disorder, have also experienced supply issues in 2025. These problems stem from various factors, including the relocation of production facilities for active ingredients and a pricing system that some in the pharmaceutical industry argue does not adequately compensate for production costs. Antidepressant use in France has seen a significant increase, rising sixfold between 1980 and 2001, but has remained stable since then. According to the OECD, France is no longer among the European countries with the highest antidepressant consumption, with 63.5 doses consumed per 1,000 people daily. This is far below the rates seen in Iceland (168.3 doses) and Portugal (151.9 doses).